Global Kidney Cancer Drugs Market – Industry Trends and Forecast to 2030

Kidney Cancer Drugs Market Analysis and Size

The kidney cancer drugs market is anticipated to witness major growth during the forecast period. Increasing incidence of chronic kidney diseases globally and the rising markets are the factors that are responsible for increasing this market. Kidney cancer accounts for around 2.0% of total adult malignancies worldwide and makes up for 3.8% of all new cancer cases in U.S. The growth of kidney cancer drugs market is improved by the increasing cases of kidney diseases and the increase in R&D activities conducted by several pharmaceutical companies.

Data Bridge Market Research analyses a growth rate in the kidney cancer drugs market in the forecast period 2023-2030. The expected CAGR of kidney cancer drugs market is tend to be around 5.90 % in the mentioned forecast period. The market is valued at USD 6.30 million in 2022, and it will grow upto USD 9.9 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Kidney Cancer Drugs Market Scope and Segmentation

Market Definition

Kidney cancer drugs are a great boon to patients in controlling numerous problems which cause conditions and complications during kidney diseases. It helps treat several symptoms of kidney failure such as loss of appetite, anemia, and feeling out of breath. However, kidney transplantation is considered to be the most standard treatment for advanced kidney disease.  At the advanced stage of kidney cancer, where removal of the cancerous cells is essential, surgical removal of kidney is done to get cure from the disease.

Kidney Cancer Drugs Market Dynamics

Drivers

• Increased Incidence of Kidney Diseases

The increasing incidence of chronic kidney disease globally is majorly responsible for driving the growth of the kidney cancer drugs market. As per the National Kidney Foundation, around 10% of the population is majorly affected by chronic kidney disease (CKD). Renal cell carcinoma accounts for more than 90.0% of all kidney cancers while renal pelvis cancer makes up for <10.0% of microscopically confirmed kidney carcinomas. Clear cell renal cell carcinoma is the most widespread subtype of renal cell carcinoma, affecting around 70.0% of patients with RCC. This demands the increase in kidney cancer drugs.

• Increasing Demand for Immunotherapies

Increasing preference for novel immunotherapies and immune-oncologic agents will push the wide use of targeted therapies to particular patient subpopulations. Programmed death-1 (PD-1) inhibitors are meant to displace TKIs and mTOR inhibitors and work as the primary care in first-and second-line RCC settings. Combination regimens, especially those including PD-1 inhibitors, will be launched in the first-line setting to target major unmet needs, improve progression-free survival, overcome tumor resistance, and maintain the quality of life. Thus, this treatment type is enhancing the market growth.

Opportunities

• Higher Trend of Drug Approvals

The rising approval from the FDA and other authorities for the kidney cancer drugs creates several opportunities for the market growth. For instance, Marck Sharp and Dohme Corp. got approval from Food and Drug Administration (FDA) for KEYTRUDA for the treatment of patients suffering from kidney cancer cell carcinoma. Therefore, all these factors enhance the market expansion.

• Increasing Healthcare Expenditure

The rising expenditure that several organizations are funding lead to the growth of the market. For instance, China offers strong opportunities for market expansion because of the ongoing Healthy China 2020 healthcare reform and the removal of price caps on all medicine categories. The Chinese government has started a supportive 12th Five-Year Plan measures which targets biotechnology as a vital development sector. Moreover, the presence of a large target base with strong unmet clinical needs is expected to boost the market growth.

 Restraints/Challenges

• Side Effects of Kidney cancer Drugs

The major side effects related with these kidney cancer drugs could limit the growth of the kidney cancer drugs market during the forecast period. Effects such as loss of appetite, fever, rashes, can impede the market growth.

• High Cost of Treatment

The huge expenditure associated with these agents hamper the market growth. The generic renal cancer treatments are quite expensive and thus is not affordable to many of the patients. Thus, it hampers the market growth.

This global kidney cancer drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global kidney cancer drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Kidney Cancer Drugs Market            

The COVID-19 pandemic negatively impacted the market due to the reduction in R&D activities for kidney cancer drugs. For instance, per the data published by the National Center for Biotechnology Information in May 2020, the physicians were focused on developing the SARS-CoV-2 vaccine to avoid the rapid spread of the virus globally. Capacity for surgery has also been minimized as theater space and ventilators have been requisitioned to provide extra critical care capacity for COVID-19 patients. Thus, overall, COVID-19 had a major impact on the kidney cancer drugs market.

Recent Developments

• In 2022, Clinical Hospital of the Faculty of Medicine of Ribeirão Preto partnered with Bristol Myers Squibb and São Paulo Research Foundation for the launch of Nivolumab- new drug on renal cancer. Nivolumab is in the Phase 2 clinical trial whose study was initiated in January 18 2022.

Global Kidney Cancer Drugs Market Scope

The kidney cancer drugs market is segmented on the basis of type, drug type, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Renal Cell Carcinoma (RCC)
• Papillary Renal Cell Carcinoma
• Chromophobe Renal Cell Carcinoma
• Unclassified Renal Cell Carcinoma
• Transitional Cell Carcinoma
• Wilms Tumor (Nephroblastoma)
• Renal Sarcoma
• Angiomyolipoma
• Oncocytoma
• Others

Drug Class

• Monoclonal Antibodies
• Trastuzumab
• Pertuzumab
• mTOR Inhibitors
• Sirolimus
• Everolimus
• Temsirolimus
• Immune Checkpoint Inhibitor
• Atezolizumab
• Avelumab
• Durvalumab
• Combined Therapies
• Interleukin-2
• Alpha-Interferon
• Others

Drug Type

• Branded
• Generic

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Kidney Cancer Drugs Market Regional Analysis/Insights

The kidney cancer drugs market is analyzed and market size insights and trends are provided by type, drug type, drug class, distribution channel and end-user as referenced above.

The major countries covered in the kidney cancer drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a highest growth for kidney cancer drugs market throughout the forecasted period due to high smoking, hypertension and diabetic population, and wide presence of major key manufactures of the product.

North America dominates the market due to the wide presence of increased healthcare expenditure and favourable reimbursement policies for the treatment. Furthermore, Europe accounts the second largest market share because of the increased genetic disorders and presence of refined medical facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Kidney Cancer Drugs Market Share Analysis

The kidney cancer drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to kidney cancer drugs market.

Key players operating in the kidney cancer drugs market include:

• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Dr. Reddy's Laboratories Ltd (India)
• Endo International plc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Sun Pharmaceutical Industries Ltd (India)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Lupin (India)
• Cipla Inc (India)
• Aurobindo Pharma (India)
• Fresenius SE & Co. KGaA (Germany)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)

SKU-57032